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Editorial on the Research Topic
Inflammation and Biomarkers in Osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis affecting more than 500 million people
globally (1). It accounts for more pain and functional disability than any other musculoskeletal
disease and is an important source of high societal and economic costs (2). Although the
pathophysiology of OA is poorly understood (3), the risk factors associated with disease
development are well-established. They include age (4), obesity (5), sex (6), previous incidence of
joint injuries (7, 8), meniscal damage (9), joint instability (10), malalignment (11), genetics (12),
bone shape (including anatomical deformities) (13), muscle weakness and sarcopenia (14), and
metabolic disease (15–17). Although OA can affect any synovial joint, including joints in the hand,
according to studies on the global burden of disease in 2010 (18) and 2017 (19), knee OA represents
the greatest societal burden.
Beside mechanical derangement, inflammation plays a key role in the pathogenesis and
progression of OA (20, 21). However, the inflammation associated with OA is not the same type and
grade that is associated with rheumatoid arthritis (RA) and other inflammatory diseases of joints
(22). It is becoming increasingly accepted that “low-grade” inflammation and the mechanisms that
regulate it are relevant not only to joint pain and disability in OA (23), but also to joint trauma and
the biomechanical damage sustained to joint tissues (24–26). Persistent synovitis as well as damage
to the subchondral bone have been considered to play major roles in joint destruction, particularly
in knee OA (27, 28). The association of meniscal damage with OA progression has highlighted the
role of the meniscus and its biomechanical role in the joint (29–31). Therefore, the menisci may
also participate in the inflammatory scenario of joints affected by OA (32).
Another important contributor to the process of “low-grade” inflammation in OA is the
synovium (23, 33). There is evidence of cross-talk between articular cartilage, subchondral bone
and synovium. Mechanistic evidence comes from in vitro and animal studies and clinical evidence
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from studies on patients with OA (34, 35). Synovial cells,
particularly type A macrophage-like synoviocytes, are likely to
be the major source of pro-inflammatory mediators within the
joint (36). Moreover, there are differences in the profile of
pro-inflammatory cytokine production in classically activated
(M1) and alternatively activated (M2) macrophages (37, 38).
Macrophage polarisation is an issue that may be relevant not only
to emerging targeted therapies but also to ongoing efforts aimed
at discriminating the different molecular endotypes and clinical
phenotypes of OA (39, 40).
Biochemical markers (also called molecular markers,
signature molecules or biomarkers) are biological molecules
found in body fluids, or tissues that may be used as indicators
of physiological and pathophysiological processes. They can
be defined as “a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a
therapeutic intervention.” (41). Biomarkers may be used
to see how well patients respond to new treatments and
interventions for a disease or condition. In OA biomarkers may
be used to understand disease pathogenesis, study progression
and define the molecular endotypes (42, 43). Biomarkers have
been used very effectively to identify molecular endotypes and
clinical phenotypes in other disease areas. For example, in
asthma, biomarkers have been used to identify phenotypes and
endotypes that characterise severe asthma (44, 45). However, in
the field of OA we are lagging behind and need to catch up in
order to enhance clinical trials and facilitate drug development.
Biomarkers of early OA represent a major unmet need and
more research needs to be done to identify biomarkers that
characterise early events in the pathogenesis of OA.
The aim of this Research Topic was to assemble a
comprehensive collection of authoritative articles focusing on
fundamentals of the inflammatory scenario in OA joints
and their relevance to existing and emerging biomarkers in
this disease. One of the key priorities is the identification,
characterisation and validation of biomarkers that define
molecular endotypes of OA, serving as tools to discriminate
different OA phenotypes.
MicroRNAs (miRNAs) are post-transcriptional regulators that
are dysregulated in osteoarthritic tissues including the synovium.
miRNAs are important contributors to OA synovial changes and
to act as novel therapeutic targets. Tavallaee et al., reviewed the
recently published literature investigating the roles that miRNAs
play in OA-related synovial pathologies including inflammation,
matrix deposition and cell proliferation. Their analysis of the
literature has revealed that miRNAs contribute to synovial
homeostasis, inflammation, fibrosis, angiogenesis, cell survival
and cell apoptosis, contributing to OA synovial pathology.
The inflammation fuelled bymetabolic imbalance, also known
as “meta-inflammation,” is a type of chronic (long-lasting),
persistent but “low-grade” systemic inflammation caused by
multiple components involved in metabolic syndrome (MetS),
including central obesity, adipokine dysregulation, and impaired
glucose tolerance. Gratal et al., reviewed the literature focusing
on purinergic regulation in OA cartilage and how different
components of MetS modulate the purinergic system in OA.
They described the critical role of receptors, such as adenosine
A2A receptor (A2AR) and ATP P2X7 receptor in OA and assess
how nucleotides regulate the inflammasome in OA.
Villalvilla et al. conducted an animal study using rabbits to
investigate the effect of hypercholesterolemia induced by high-
fat diet (HFD) in cartilage from OA rabbits, and how oxLDL
affect human chondrocyte inflammatory and catabolic responses.
They found that HFD intake does not modify cartilage structure
or pro-inflammatory and catabolic gene expression and protein
presence, both in healthy andOA animals. Their study concluded
that dietary cholesterol intakemay not be deleterious for articular
cartilage but altered cholesterol metabolism may be involved in
the associations observed in human disease.
Although biomarkers are important in OA research, clinical
trials, and drug development, they have not yet had any
significant impact on the clinical management of the OA
and follow-up. Bernotiene et al., argued that emerging nano-
technologies and immunoassay platforms that are already
impacting on routine diagnostics and monitoring in other
diseases could potentially serve as technological and strategic
examples for enhanced clinical management of OA. Their review
article explored the implementation of such technologies in
OA research and therapy and discussed the challenges that
hinder the development, testing, and implementation of new
OA biochemical marker assays utilising emerging multiplexing
technologies and biosensors.
Rajandran et al., evaluated the association between
biomarkers of innate immunity and magnetic resonance
imaging (MRI) features of early and late stages of knee
OA. They investigated biomarkers of innate immunity
associated with meniscal extrusion and synovial inflammation
in earlier stage and bone marrow lesions (BMLs) in later
stages of knee OA. They also observed associations between
pro-inflammatory biomarkers and various MRI features
in the early stages of knee OA. Their exploratory study
supported the association between biomarkers of activated
macrophages and synovial inflammation in the early stages of
knee OA.
Lambert et al., reviewed the literature focusing on damage-
associated molecular patterns (DAMPs) as biomarkers and
potential therapeutic targets for OA. Their paper highlighted
the central role of DAMPs in the interplay between immune
responses and inflammation in OA.
Sun et al., used a rat model of OA to determine whether
switching from an obesogenic diet to a normal chow
diet can mitigate the detrimental effects of inflammatory
pathways that contribute to OA pathology. Their results
indicated that dietary switching from an obesogenic diet to
a normal diet reduces body weight and restores metabolic
parameters and suppresses synovial inflammation. They
concluded that obesogenic diets induce systemic and
synovial inflammation and dietary switching may be
used as an intervention to slow down the progression
of OA.
Work by de Melo Nunes et al. examined the chemical
composition of glycosaminoglycans (GAGs) from normal and
osteoarthritic cartilage and a reported reduced sulphur content
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in GAGs from OA patients, which is associated with a reduced
zeta potential.
Finally, Zhang et al., reviewed the literature on synovial
fibrosis in OA, establishing the concept that fibrosis is an eventual
outcome of inflammation in OA. Therefore, new interventions
are needed to slow the progression of fibrosis in OA and
associated co-morbidities. They proposed the combined use of
anti-fibrotic drugs with potential for therapy in OA.
We hope that you enjoyed reading these papers as much as we
enjoyed editing them for this Research Topic in the rheumatology
section of Frontiers in Medicine.
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